Cargando…

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive tumors, with a low rate of survival, likely due to the tendency of the tumor for early local and distant spread. Pancreatic cancer accounts for about 3% of all cancers in the US and about 7% of all cancer deaths. Surgical res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lekka, Kyriaki, Tzitzi, Evanthia, Giakoustidis, Alexander, Papadopoulos, Vassilios, Giakoustidis, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Hepato-Biliary-Pancreatic Surgery 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558121/ https://www.ncbi.nlm.nih.gov/pubmed/31225409 http://dx.doi.org/10.14701/ahbps.2019.23.2.97

Ejemplares similares

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma
por: Giakoustidis, Alexandros, et al.
Publicado: (2018)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition
por: Soweid, Assaad M.
Publicado: (2017)

Primary gigantic leiomyosarcoma of the liver treated with portal vein embolization and liver resection
por: Giakoustidis, Dimitrios, et al.
Publicado: (2017)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine
por: Vernuccio, Federica, et al.
Publicado: (2021)

Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review
por: Gavriilidis, Paschalis, et al.
Publicado: (2015)

The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
por: Sakaguchi, Tatsuma, et al.
Publicado: (2020)

Editorial: Neuroendocrine tumors of the gastrointestinal tract, liver, and pancreas: current management and treatment strategies
por: Giakoustidis, Alexandros, et al.
Publicado: (2023)

Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
por: Sulciner, Megan L., et al.
Publicado: (2022)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: EUS oriented
por: Iordache, Sevastiţa, et al.
Publicado: (2017)

Bilateral Morgagni Hernia: Primary Repair without a Mesh
por: Papanikolaou, Vassilios, et al.
Publicado: (2008)

Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101
por: Costa Neves, Mafalda, et al.
Publicado: (2015)

Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review
por: Fiflis, Stylianos, et al.
Publicado: (2023)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice?
por: Zerbi, Alessandro, et al.
Publicado: (2017)

Controversies in the Management of Borderline Resectable Proximal Pancreatic Adenocarcinoma with Vascular Involvement
por: Tucker, Olga N., et al.
Publicado: (2008)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Diagnostic work-up and advancement in the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
por: Koffas, Apostolos, et al.
Publicado: (2023)

Neutrophil-to-lymphocyte ratio as a prognostic factor for survival in patients with colorectal liver metastases: A systematic review
por: Papakonstantinou, Menelaos, et al.
Publicado: (2022)

Emergency Open Incarcerated Hernia Repair with a Biological Mesh in a Patient with Colorectal Liver Metastasis Receiving Chemotherapy and Bevacizumab Uncomplicated Wound Healing
por: Giakoustidis, Alexandros, et al.
Publicado: (2014)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging
por: D’Onofrio, Mirko, et al.
Publicado: (2017)

Jejunojejunal Intussusception due to Metastatic Melanoma Seven Years after the Primer
por: Giakoustidis, Alexander, et al.
Publicado: (2017)

Erratum: The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging
Publicado: (2018)

The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma
por: Kawahara, Kenji, et al.
Publicado: (2022)

Median arcuate ligament syndrome often poses a diagnostic challenge: A literature review with a scope of our own experience
por: Giakoustidis, Alexandros, et al.
Publicado: (2023)

Advances in the management of pancreatic ductal adenocarcinoma
por: O’Kane, Grainne M., et al.
Publicado: (2021)

Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management
por: Fawaz, Ali, et al.
Publicado: (2022)

Contemporary Management of Localized Resectable Pancreatic Cancer
por: Kommalapati, Anuhya, et al.
Publicado: (2018)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
por: Giovinazzo, Francesco, et al.
Publicado: (2020)

Tumor Biology: Is It Time to Redefine Unresectability? An Extraordinary Case of Gastroesophageal Junctional Adenocarcinoma
por: Gaya, Andy, et al.
Publicado: (2015)

Irreversible electroporation in borderline resectable pancreatic adenocarcinoma for margin accentuation
por: Papoulas, Michail, et al.
Publicado: (2018)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort study
por: Secanella, Luis, et al.
Publicado: (2022)

CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Maggino, Laura, et al.
Publicado: (2022)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection
por: Flis, Vojko, et al.
Publicado: (2016)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
por: Chen, Emerson Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_teiftic9lga614oi0ipn8kifd2